专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明申请

US20110034495A1 Method of Modulating Stress-Activated Protein Kinase System 审中-公开
标题翻译：调节应激活化蛋白激酶系统的方法
公开(公告)号：US20110034495A1
公开(公告)日：2011-02-10
申请号：US12094230
申请日：2006-11-22
申请人： Scott D. Seiwert , Karl Kossen , Vladimir Serebryany
发明人： Scott D. Seiwert , Karl Kossen , Vladimir Serebryany
IPC分类号： A61K31/506 , C07D471/02 , C07D401/14 , C07D231/10 , C07D401/04 , A61K31/4365 , A61K31/415 , A61K31/4439 , A61P29/00 , A61P11/00 , A61P19/02 , A61P17/00 , A61P31/00 , A61P3/10
CPC分类号： C07D495/04
摘要： A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.
摘要翻译：在2-位被羰基或磺酰基连接的吡咯烷-1-基或相关部分取代的一系列噻吩并[2,3-b]吡啶-6（7H） - 酮衍生物，是p38MAP激酶的抑制剂因此在药物中使用，例如用于治疗和/或预防免疫或炎症性疾病。

112. 发明授权

US07767700B2 Method of providing pirfenidone therapy to a patient 有权
标题翻译：向患者提供吡非尼酮治疗的方法
公开(公告)号：US07767700B2
公开(公告)日：2010-08-03
申请号：US11959338
申请日：2007-12-18
申请人： Williamson Ziegler Bradford
发明人： Williamson Ziegler Bradford
IPC分类号： A61K31/44
CPC分类号： A61K31/4418 , A61J1/03 , A61J1/035 , A61J2205/50 , A61K31/4412
摘要： The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
摘要翻译：本发明涉及减少与吡非尼酮（5-甲基-1-苯基-2-（1H） - 吡啶酮）治疗相关的不良事件的方法。本发明公开了一种优化的剂量递增方案，其导致患者对施用吡非尼酮的不良事件的耐受性增加。本发明还公开了可以与剂量递增方案结合使用的起动器组件。

113. 发明授权

US07696236B2 Method of providing pirfenidone therapy to a patient 有权
公开(公告)号：US07696236B2
公开(公告)日：2010-04-13
申请号：US12427532
申请日：2009-04-21
申请人： Williamson Z. Bradford
发明人： Williamson Z. Bradford
IPC分类号： A61K31/44
CPC分类号： A61K31/4418 , A61J1/03 , A61J1/035 , A61J2205/50 , A61K31/4412
摘要： The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.

114. 发明授权

US07638488B2 Use of alpha-glucosidase inhibitors to treat alphavirus infections 失效
标题翻译：使用α-葡萄糖苷酶抑制剂治疗甲病毒感染
公开(公告)号：US07638488B2
公开(公告)日：2009-12-29
申请号：US11370535
申请日：2006-03-07
申请人： Lawrence M. Blatt , Hua Tan , Scott Seiwert
发明人： Lawrence M. Blatt , Hua Tan , Scott Seiwert
IPC分类号： A61K38/16 , A61K31/70 , A61K31/715 , A61K31/44 , A61K31/445
CPC分类号： A61K31/7008 , A61K31/445 , A61K31/7034 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.
摘要翻译：本发明提供了在患有黄病毒感染的个体中治疗黄病毒感染（包括丙型肝炎病毒（HCV）感染）的方法。在一些实施方案中，所述方法包括向有需要的个体施用有效量的抑制膜结合的α-葡糖苷酶抑制剂的酶活性的试剂。在其它实施方案中，所述方法包括向有需要的个体施用有效量的α-葡糖苷酶抑制剂和至少一种另外的治疗剂。

115. 发明授权

US07566729B1 Modifying pirfenidone treatment for patients with atypical liver function 有权
标题翻译：改变吡非尼酮治疗非典型肝功能的患者
公开(公告)号：US07566729B1
公开(公告)日：2009-07-28
申请号：US12428393
申请日：2009-04-22
申请人： Williamson Ziegler Bradford , Javier Szwarcberg
发明人： Williamson Ziegler Bradford , Javier Szwarcberg
IPC分类号： A61K31/445
CPC分类号： A61K31/445 , Y02A50/401 , Y02A50/411
摘要： Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage.
摘要翻译：提供了用于向依托吡非尼酮给药反应呈现出肝功能异常生物标志物的患者施用吡非尼酮的方法。所述方法包括以低于全部目标剂量的剂量给予患者吡非尼酮一段时间，然后以完全目标剂量施用于患者吡非尼酮。

116. 发明申请

US20090148407A1 Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication 审中-公开
标题翻译：丙型肝炎病毒复制的新型大环抑制剂
公开(公告)号：US20090148407A1
公开(公告)日：2009-06-11
申请号：US11996902
申请日：2006-07-17
申请人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
发明人： Lawrence M. Blatt , Scott D. Seiwert , Steven W. Andrews , Pierre Martin , Andreas Schumacher , Bradley Barnett , C. Todd Eary , Robert Kaus , Timothy Kercher , Weidong Liu , Michael Lyon , Paul Nichols , Bin Wang , Tarek Sammakia , April Kennedy , Yutong Jiang
IPC分类号： A61K38/21 , C07K5/12 , A61K38/12 , C07D209/18 , C12N9/99 , A61K39/395
CPC分类号： C07K5/0806 , A61K38/00 , A61K38/1793 , A61K38/212 , A61K38/217 , A61K38/2292 , A61K38/55 , C07D471/04 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供通式（I）至通式（VIII）的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

117. 发明申请

US20080194644A1 METHOD OF PROVIDING PIRFENIDONE THERAPY TO A PATIENT 有权
标题翻译：向患者提供派尼酮治疗方法
公开(公告)号：US20080194644A1
公开(公告)日：2008-08-14
申请号：US11959338
申请日：2007-12-18
申请人： Williamson Z. Bradford
发明人： Williamson Z. Bradford
IPC分类号： A61K31/4412
CPC分类号： A61K31/4418 , A61J1/03 , A61J1/035 , A61J2205/50 , A61K31/4412
摘要： The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
摘要翻译：本发明涉及减少与吡非尼酮（5-甲基-1-苯基-2-（1H） - 吡啶酮）治疗相关的不良事件的方法。本发明公开了一种优化的剂量递增方案，其导致患者对施用吡非尼酮的不良事件的耐受性增加。本发明还公开了可以与剂量递增方案结合使用的起动器组件。

118. 发明授权

US07407973B2 Use of pirfenidone in therapeutic regimens 失效
标题翻译：吡非尼酮在治疗方案中的应用
公开(公告)号：US07407973B2
公开(公告)日：2008-08-05
申请号：US10574631
申请日：2004-10-21
申请人： Osman N. Ozes , Lawrence M. Blatt , Scott D. Seiwert
发明人： Osman N. Ozes , Lawrence M. Blatt , Scott D. Seiwert
IPC分类号： A61K31/445
CPC分类号： A61K31/47 , A61K31/4412 , A61K38/212 , A61K38/217 , A61K45/06 , G01N33/5091 , Y02A50/411 , A61K2300/00
摘要： The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.
摘要翻译：本发明提供了治疗病症的方法以及在个体细胞中抑制应激活化蛋白激酶（SAPK）的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物 ; 将来自个体的生物样品中的后处理SAPK活性水平与预处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。本发明提供了治疗病症的方法以及在个体细胞中抑制SAPK的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物; 将来自个体的生物样品中的第二后处理SAPK活性水平与第一后处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。

119. 发明申请

US20080102056A1 Marketing System for Improving Patient Compliance and Methods and Devices Relating to Same 审中-公开
标题翻译：用于改善患者依从性的营销系统和与之相关的方法和设备
公开(公告)号：US20080102056A1
公开(公告)日：2008-05-01
申请号：US10543466
申请日：2004-02-02
申请人： Williamson Ziegler Bradford , James Pennington , Stephen Rosenfield
发明人： Williamson Ziegler Bradford , James Pennington , Stephen Rosenfield
IPC分类号： A61K38/21 , G06Q50/00 , A61P11/00 , A61M5/14 , G06Q30/00
CPC分类号： A61K38/217 , G06Q30/0217
摘要： The present invention provides a marketing system and methods for marketing a dosage form comprising interferon gamma (IFN-γ) to a patient in need thereof, for the treatment of idiopathic pulmonary fibrosis (IPF). The present invention further provides a method for increasing patient compliance. The present invention further provides methods of treatment and dosage forms compatible for use in the marketing systems and methods of the invention.
摘要翻译：本发明提供了一种营销系统和方法，用于向有需要的患者销售包含干扰素γ（IFN-γ）的剂型，用于治疗特发性肺纤维化（IPF）。本发明还提供了一种增加患者依从性的方法。本发明还提供了与本发明的营销系统和方法相兼容的治疗和剂型的方法。

120. 发明申请

US20080019942A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION 失效
标题翻译： HEPATITIS C VIRUS REPLICATION的新型抑制剂
公开(公告)号：US20080019942A1
公开(公告)日：2008-01-24
申请号：US11773912
申请日：2007-07-05
申请人： Scott Seiwert , Leonid Beigelman , Lawrence Blatt , Timothy Kercher , April Kennedy , Steven Andrews
发明人： Scott Seiwert , Leonid Beigelman , Lawrence Blatt , Timothy Kercher , April Kennedy , Steven Andrews
IPC分类号： A61K38/21 , A61K31/4035 , A61K31/416 , A61K31/437 , C07D209/44 , C07D471/04 , C07D231/54 , A61P31/12 , A61K31/505 , A61K31/52
CPC分类号： C07D403/14 , C07D231/56 , C07D471/04
摘要： The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
摘要翻译：实施方案提供了通式I的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式II的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案提供了通式III的化合物，以及包含主题化合物的组合物，包括药物组合物。实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式